Research programme : peptide-based radioligands - Curasight
Alternative Names: Peptide-based radioligandsLatest Information Update: 11 Mar 2024
At a glance
- Originator Curasight
- Class Antineoplastics; Imaging agents; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer